B cells are important in the pathogenesis of many, and perhaps all, immune-mediated diseases. Each B cell expresses a single B cell receptor (BCR) 1 , and the diverse range of BCRs expressed by the total B cell population of an individual is termed the 'BCR repertoire' . Our understanding of the BCR repertoire in the context of immune-mediated diseases is incomplete, and defining this could provide new insights into pathogenesis and therapy. Here, we compared the BCR repertoire in systemic lupus erythematosus, anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, Crohn's disease, Behçet's disease, eosinophilic granulomatosis with polyangiitis, and immunoglobulin A (IgA) vasculitis by analysing BCR clonality, use of immunoglobulin heavy-chain variable region (IGHV) genes and-in particular-isotype use. An increase in clonality in systemic lupus erythematosus and Crohn's disease that was dominated by the IgA isotype, together with skewed use of the IGHV genes in these and other diseases, suggested a microbial contribution to pathogenesis. Different immunosuppressive treatments had specific and distinct effects on the repertoire; B cells that persisted after treatment with rituximab were predominately isotype-switched and clonally expanded, whereas the inverse was true for B cells that persisted after treatment with mycophenolate mofetil. Our comparative analysis of the BCR repertoire in immunemediated disease reveals a complex B cell architecture, providing a platform for understanding pathological mechanisms and designing treatment strategies.
B cells are important in the pathogenesis of many, and perhaps all, immune-mediated diseases. Each B cell expresses a single B cell receptor (BCR)
, and the diverse range of BCRs expressed by the total B cell population of an individual is termed the 'BCR repertoire' . Our understanding of the BCR repertoire in the context of immune-mediated diseases is incomplete, and defining this could provide new insights into pathogenesis and therapy. Here, we compared the BCR repertoire in systemic lupus erythematosus, anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, Crohn's disease, Behçet's disease, eosinophilic granulomatosis with polyangiitis, and immunoglobulin A (IgA) vasculitis by analysing BCR clonality, use of immunoglobulin heavy-chain variable region (IGHV) genes and-in particular-isotype use. An increase in clonality in systemic lupus erythematosus and Crohn's disease that was dominated by the IgA isotype, together with skewed use of the IGHV genes in these and other diseases, suggested a microbial contribution to pathogenesis. Different immunosuppressive treatments had specific and distinct effects on the repertoire; B cells that persisted after treatment with rituximab were predominately isotype-switched and clonally expanded, whereas the inverse was true for B cells that persisted after treatment with mycophenolate mofetil. Our comparative analysis of the BCR repertoire in immunemediated disease reveals a complex B cell architecture, providing a platform for understanding pathological mechanisms and designing treatment strategies.
During the development of B cells in the bone marrow (or fetal liver) 2 , recombination of immunoglobulin genes forms the 'naive' BCR repertoire, which is modified by the removal or suppression of selfreactive B cells to reduce the chance of autoimmune disease 3 (although 20-40% of B cells remain autoreactive 4 ). Further diversification of the repertoire occurs after B cells respond to antigen. Many B cells undergo 'isotype switching' , in which stepwise DNA deletion and recombination from immunoglobulin M (IgM) generates downstream isotypes (IgG1, IgG2, IgG3 and IgG4, IgA1 and IgA2, IgD and IgE) that confer distinct functional characteristics and roles in disease 5, 6 . Delineation of isotypes is thus vital for a full analysis of the BCR repertoire. Further diversification of BCRs occurs in specialized germinal centres, in which somatic hypermutation (SHM) of genes that encode the variable (V) regions of antibodies may enhance BCR affinity and specificity 7 . This diversification of B cell clones after exposure to antigen is tempered by tolerance checkpoints to reduce the risk of autoimmunity 8 . The peripheral BCR repertoire is thus a composite of both the naive repertoire and that generated by antigenic encounter.
Features of the BCR repertoire have been correlated with both microbial interactions and immune-mediated diseases (IMDs); specific IGHV regions recognize commensal and/or pathogenic microorganisms or are associated with IMDs (Supplementary Table 1 ). We analysed the BCR repertoire in 209 individuals across 6 IMDs (Extended Data Fig. 1a , Supplementary Tables 2, 3 ), comparing (i) IMDs that are characterized by autoantibody responses against either single dominant autoantigens (ANCA-associated vasculitis (AAV)) or multiple autoantigens (systemic lupus erythematosus (SLE)); (ii) IMDs that are not thought to be autoimmune (Crohn's disease, Behçet's disease); and (iii) IMDs for which there is incomplete evidence of B cell involvement or autoimmunity (eosinophilic granulomatosis with polyangiitis (EGPA; formerly Churg-Strauss syndrome), IgA vasculitis (IgAV; formerly Henoch-Schönlein purpura)). For disease descriptions, see Supplementary Discussion.
We developed a method to barcode, amplify and sequence BCR repertoires from RNA that encodes the antigen-binding (IgH (VDJ)) and constant regions of the BCR heavy chain. This method facilitates analysis of isotype class and subclass, as well as allowing the quantitation of clone frequency and correction of PCR-or sequencing-based error 9 (Extended Data Fig. 1b ). We then analysed the BCR repertoire in sorted B cells from 19 healthy control individuals (Supplementary Discussion, Extended Data Figs. 1, 2) to develop methods to control for the effects of age and different cellular RNA content (Methods, Extended Data Figs. 2, 3a-c, Supplementary Table 4 ). We define the 'normalized' isotype use-that is, the percentage of unique VDJ sequences per isotype-thus counting the contribution of each B cell to the repertoire only once.
Comparative studies in IMDs have often been confounded by differences in disease duration, activity and treatment. We therefore specifically recruited patients for whom there was objective evidence of active disease and who had not yet commenced treatment (although stable doses of low-level therapy, which are known not to affect BRC repertoire, were permitted; Methods, Supplementary Discussion). The majority of the patients were newly diagnosed. For all patients, the number of B cells sampled was higher than the number of unique BCR sequences detected ( Supplementary Table 3 ). We compared isotype use in repertoires from unseparated peripheral blood mononuclear cells (PBMCs) in healthy controls and patients with IMDs ( Fig. 1a, b , Extended Data Fig. 3d ). Compared to the control samples, IgA was over-represented in all diseases except AAV and EGPA, and particularly so in SLE and Crohn's disease. This corresponded with an increase in the levels of serum IgA, which was most pronounced in SLE ( Fig. 1c ). Expression of IgE was increased in SLE, Crohn's disease and-in particular-EGPA ( Fig. 1b , Extended Data Fig. 3d, e ), which also exhibited an increase in IgG3. Isotype use in AAV was similar to healthy controls. There is therefore marked variation in isotype use in IMDs, and IgA is the dominant isotype in diseases such as SLE and Behçet's disease.
The diversity of the BCR repertoire is driven in part by differential use of IGHV genes, as well as non-template additions and deletions of nucleotides. Some individual genes, and IGHV subgroups (defined by structural similarity 10 ), preferentially bind microbial antigens and/or have been associated with autoimmunity (Supplementary Table 1 ). We examined the frequency of IGHV genes in naive and antigen-experienced B cells across IMDs (Fig. 1d , Extended Data Fig. 4a , Supplementary Data 2, 3). Expression of genes of the IGHV4 family was increased in Crohn's disease, SLE and EGPA, as was that of Letter reSeArCH IGHV6-1. Notably, IGHV4-34 binds both autoantigens 11 and commensal bacteria 12 , and has been associated with SLE 13 . Our data extend this association of IGHV4-34 (and its 9G4 idiotype) with SLE to EGPA and Crohn's disease (Extended Data Fig. 4b ). Both IGHV6-1 and IGHV4-59 have been associated with autoreactivity (Supplementary Table 4 ). The associations between IGHV genes and these IMDs were seen in both the predominantly 'naive' and the 'post-antigenic' compartments, and in both non-expanded and expanded clones (Extended Data Fig. 4a ), raising the possibility that they are not purely a consequence of selective expansion after disease development (except in Crohn's disease, in which the differences in IGHV genes were predominantly 'pre-antigenic'). Genes of the V1 family were over-represented in IMDs, particularly Crohn's disease and Behçet's disease. The most striking association was that of Behçet's disease with IGHV1-46, IGHV1-3 and IGHV1-69-all of which have been previously associated with infection in both the naive and post-antigenic repertoires (previous studies are listed in Supplementary Table 1 ). Reduced representation of IGHV genes was also seen in some diseases, reflecting either a proportional reduction due to the increased frequency of other IGHV genes, or real disease associations. Levels of SHM did not vary between diseases (Extended Data Fig. 4c ).
An increase in the length of complementarity-determining region 3 (CDR3) of the BCR is associated with antibody polyreactivity and autoimmunity 14 . Building on previous work 9 , we found an association between the length of CDR3 and the use of IGHV genes in healthy individuals (Extended Data Figs. 2, 4d ). In the case of patients with IMDs, increased CDR3 length was found in SLE (IgG and IgA) and Crohn's disease (unswitched B cells) (Extended Data Fig. 4c) .
B cell clones are defined by sharing a unique VDJ rearrangement, and can be characterized by size (clonal expansion) and diversification (owing to SHM and isotype switching). Using a clone-sampling method to visualize the BCR repertoire (Supplementary Discussion, Extended Data Fig. 5 ), we found no differences between samples from healthy controls and patients with AAV or IgAV, reduced clonality in Behçet's disease, but increased clonal expansion and complexity in Crohn's disease, EGPA and SLE (Supplementary Data 5, 6). We
Class-switched Measure of unevenness of the number of unique VDJ sequences per clone (irrespective of number of RNA molecules). Controls for differential RNA per cell and removes potential biases from differential RNA per cell, e.g., from plasmablasts. Letter reSeArCH extended this analysis by determining the clonal expansion index (a measure of the 'unevenness' of the number of RNA molecules per unique VDJ region sequence, defined by the Gini index 15 ) and the clonal diversification index, defined by Renyi entropy (a measure of the unevenness of unique VDJ region sequences per clone) (Methods, Fig. 1e -g, Extended Data Fig. 6 ). Patients with Crohn's disease had increased clonal expansion and diversification across many isotypes, particularly IgA, IgG and IgM. SLE showed a similar pattern-although with increased clonality primarily in unswitched cells and with greater variation between patients-as did EGPA (but with IgE predominant for the latter). Differences in the maximum clone size were consistent with these data (Extended Data Figs. 6c, d, 7a). By contrast, patients with active AAV or IgAV showed no gross difference in clonal expansion or diversification, and in Behçet's disease both were reduced compared to controls. We then used a multivariate comparison to assess 'clonal normality' (see Methods), and found significant dissimilarity between the repertoires of patients with Crohn's disease, EGPA and SLE, compared to those of healthy individuals and patients with AAV and Behçet's disease (Extended Data Fig. 7b )-reinforcing the concept that although some diseases are associated with broad abnormalities of the BCR repertoire, others show a BCR repertoire that is comparatively normal.
Class-switch recombination (CSR) is a deletional DNA recombination process, so the order of constant regions on the chromosome defines the possible isotypes to which any given B cell can switch ( Fig. 2a , Extended Data Fig. 7c, d ). The progression of CSR between each possible constant region (switch events) may be assessed by quantifying the frequency of unique VDJ regions that share two isotypes (suggesting their common clonal origin; Fig. 2b ) after normalizing for read depth (Extended Data Fig. 7e , f). The number of class-switching types that are detectable in this analysis is reduced by the isotype ambiguity between IgA1 and IgA2, and IgG1 and IgG2, in the isotype-specific sequencing, and by alternative splicing of IgD from transcripts that contain IgM (Extended Data Fig. 8a, b ). We confirmed reported frequencies of switch events in healthy individuals 16 (Fig. 2c ). Switching differences between isotypes in IMDs usually corresponded IGHM   IGHG3  IGHG1   IGHA1   IGHG2   IGHG4  IGHE   IGHA2   IGHM   IGHG3  IGHG1   IGHA1   IGHG2   IGHG4  IGHE   IGHA2 IgD/IgM−IgG3 Each circle represents an isotype class per disease; the size of the circle is proportional to the percentage of unique BCRs that correspond to that isotype, and circles are coloured according to whether the percentage is significantly higher than (red), lower than (blue) or not different from (black) that of healthy individuals. Arrows indicate class switching between isotypes; arrow thickness is proportional to the relative frequency of CSR events for each disease, and arrows are coloured according to whether the frequency is significantly higher than (red), lower than (blue) or not different from (black) healthy individuals. P values were calculated by two-way ANOVA and the FDR was determined by the Šidák method; FDR < 0.05 was used as the threshold for significance. e, Proportion of VDJ sequences for which the closest clonal relatives are also present as the same isotype (across health and IMDs; n = 149). f, Proportion of VDJ sequences per isotype that are also observed as other isotypes (across health and IMDs; n = 149). g, Representative phylogenetic tree of an IgEassociated clone maintained over the course of therapy from a patient with EGPA who was negative for ANCA (patient 145). Colours indicate isotype use and time point for each BCR. All nodes are scaled to unitary size. For d-f, P values were calculated by two-sided Wilcoxon test; *FDR < 0.05, **FDR < 0.005, ***FDR < 0.0005 (determined by the Šidák method). For all box plots, box lines show the 25th, 50th and 75th percentiles; whiskers show the upper and lower quartiles. with differences in isotype use (Fig. 2d ). All switching was reduced in AAV and Behçet's disease. In SLE and Crohn's disease, the representation of IgA increased, and switching between IgA and IgE was seen. The increase in isotype switching in Crohn's disease appeared to be independent of isotype frequency. In EGPA, there was a striking increase in switching to IgE from all isotypes ( Fig. 2d ), particularly IgG3-perhaps secondary to the increased frequency of IgG3 (Extended Data Fig. 9a,  b ). This first-to our knowledge-systematic analysis of isotype switching in IMD reveals disease-specific increases that contribute to isotype profiles. Some of these, such as the prominence of IgG3 and IgE in EGPA, and the reduced switching in AAV and Behçet's disease, were unexpected and may be relevant to disease pathogenesis.
Our analysis of the BCR repertoire supports suggestions in the literature 17,18 that human IgE clones usually arise from clonally diversified memory cells of precursor isotypes, as in mice 19 . Consistent with this, IgE + peripheral blood B cells are commonly plasmablasts (Extended Data Fig. 2 ), have fewer closest clonal relatives that express the IgE isotype ( Fig. 2e , f, Extended Data Fig. 9c, d, Supplementary Discussion) , and probably share a clonal origin with cells that do not express IgE. IgE also commonly arises from multiple independent switch events in large clones (Fig. 2g ).
Different immunosuppressive regimens have different effects on the B cell compartment, and these can correlate with clinical efficacy 20 . We investigated the effect of treatment on the BCR repertoire in SLE and AAV, taking repeat samples at 3 or 12 months after diagnosis. Most patients were treated with rituximab (RTX; a B cell-depleting anti-CD20 monoclonal antibody) or mycophenolate mofetil (MMF; a precursor of an inosine 5′-monophosphate dehydrogenase inhibitor that predominantly affects proliferating cells 21 ). These regimens were standardized based on international guidelines, but not administered according a formal protocol (reflecting real-world clinical practice) and were accompanied by similar steroid and subsequent maintenance therapy (Supplementary Discussion, Methods), allowing their effects on the BCR repertoire to be compared. MMF and RTX had markedly different effects on the repertoire ( BCRs shared between samples that were taken from patients with AAV at diagnosis and at 3 months, or between samples that were taken 3 months and 12 months after induction therapy, respectively, split between patients who became negative for serum ANCA after induction therapy versus those who remained serum-ANCA positive. h, Percentage of persistent clones that expanded by more than twofold, changed by less than twofold or decreased by more than twofold between the time of diagnosis and after induction therapy in patients with AAV (n = 12, n = 20 and n = 19 for 0-3 months, 0-12 months and 3-12 months, respectively). Letter reSeArCH increased proportion of IgM + and IgD + B cells and concomitantly led to a reduction in the number of isotype-switched B cells and a reduction in clonality, with relative preservation of both IgM clones that underwent somatic hypermutation (SHM + ) and those that did not (SHM − ) compared to switched clones. This could be consistent with a shorter half-life for switched but not IgM memory B cells in humans (as seen in mice 22 ), adding to the ongoing debate on this topic 23, 24 . Conversely, after RTX, the numbers of circulating B cells were low 25 but persisting cells were largely isotype-switched and clonally expandedpredominantly IgA in AAV and IgG1 or IgG2 in SLE. Larger studies are required to determine whether these changes in the repertoire associate with disease subsets, pathogenic clonal persistence and/or treatment efficacy. Nonetheless, this suggests that the effect of a treatment on the BCR repertoire might inform the design of therapeutic strategies (for example, the ability of MMF to reduce class-switched clones might suggest that MMF could be effective in preventing relapse after RTX therapy).
Clonal persistence 3 months after therapy was observed in over 90% of patients, and the isotype of persistent clones differed between therapies ( Fig. 3f , Extended Data Fig. 10d, e, Methods) . In AAV, reduced persistence of isotype-switched clones was associated with reduced ANCA titre (Fig. 3g ). Persistent clones could expand, undergo SHM and isotype switch despite continuing therapy (Fig. 3h ). By considering the time between the last dose of MMF or RTX and the collection of the sample, we could analyse the 'recovery' of the repertoire. After treatment with MMF, the isotype-switched population reached healthy levels after approximately one year (Fig. 3i) . By contrast, the slow reconstitution of IgD + and/or IgM + unmutated cells after RTX is consistent with the known kinetics of B cell recovery after such depletion 26 .
This study reveals profound variation in many aspects of the BCR repertoire across IMDs, both at diagnosis and after therapy. Many of the disease-associated changes have not been previously described, in particular those relating to isotype use. The changes in the BCR repertoire in these diseases illustrate deficiencies in our understanding of disease pathogenesis (Supplementary Discussion). SLE, Crohn's disease and EGPA exhibited abnormal isotype-specific clonal expansion or diversity, as well as abnormal use of the IGHV genes; such a broad dysregulation of the repertoire is consistent with their associations with multiple antibodies. Increased IgA isotype usage was expected in an intestinal disease like Crohn's disease, but not in SLE, in which IgG is implicated in pathogenesis and intestinal inflammation is not prominent 27 . These observations suggest an unanticipated commonality in the pathogenesis of SLE, Crohn's disease and EGPA, suggesting that they might share unknown drivers-perhaps within the mucosal microbiome, given known IGHV affinities for microbial antigens [11] [12] [13] 28 . EGPA also displayed an expansion of IgG3 and disproportionate switching to IgE. The IgE association was expected 29 , but whether an increased IgG3 isotype usage is important in EGPA pathogenesis remains uncertain. IgAV was associated with increased IgA isotype usage and mucosal involvement, but showed no evidence of IgA clonal expansion or abnormal use of the IGHV genes-consistent with the pathogenesis of IgAV being distinct from that of Crohn's disease. It is also possible to have severe active autoimmune disease, such as AAV, without detectable changes in the BCR repertoire; the pathogenic anti-MPO or anti-PR3 clones are presumably too infrequent to skew repertoire analysis at the PBMC level. Finally, Behçet's disease showed a marked increase in the expression of IGHV1-46, IGHV1-69 and IGHV1-3. The proteins that are encoded by these genes bind to both microbial antigens and autoantigens ( Supplementary  Table 4 ), enhancing previous speculation that infection might drive disease 30 . Future studies of the BCR repertoire that expand on this work-for example, by comparing the repertoire to the microbiome or determining the antigenic specificity of expanded clones-would be illuminating. Altogether, this comprehensive analysis of the BCR repertoire across diseases reveals a complex architecture, which may provide a platform for better understanding pathological mechanisms and designing therapeutic strategies.
Methods
Ethical approval. Ethical approval for this study was obtained from the Cambridge Local Research Ethics Committee (reference numbers 04/023, 08/H0306/21, 08/ H0308/176) and Eastern NHS Multi Research Ethics Committee (07/MRE05/44). Informed consent was obtained from all subjects enrolled. Samples from healthy participants. The inclusion criteria for healthy individuals were people aged between 20 and 77 years, with no serious co-morbidities, no direct family history of autoimmune disease, no use of immunosuppressants or steroids, and no hospitalization within the last 12 months. The healthy individual samples used for B cell sorting were recruited through the NIHR Cambridge BioResource. Samples from patients with AAV. Patients with AAV who attended or were referred to the specialist vasculitis unit at Addenbrooke's Hospital, Cambridge between July 2004 and June 2016 were enrolled. Active disease at presentation was defined by at least one major or three minor criteria using the Birmingham Vasculitis Activity Score (BVAS) 31 and the clinical impression that induction immunosuppression would be required. Prospective disease monitoring was undertaken monthly with serial BVAS assessment 31 and serum ANCA status (Supplementary Discussion). Of a total of 54 patients, 41 were sampled at diagnosis and 13 at disease flare as defined above. A minority of patients (11/54) had received prior treatment with oral prednisolone, and 3 patients had received azathioprine within 6 months before sampling. Patients on low-dose steroids and azathioprine have been analysed separately, and their inclusion does not affect any of the findings described in this study. Samples from patients with SLE. The SLE cohort comprised patients who attended or were referred to the Addenbrooke's Hospital specialist vasculitis unit between July 2004 and June 2016 who met at least four American College of Rheumatology SLE criteria 32 and presented with active disease. Active disease was defined as meeting all three of the following prospectively defined criteria: new British Isles Lupus Assessment Group (BILAG) score A or B in any system, clinical assessment of active disease by the reviewing physician and increase in immunosuppressive therapy as a result. After treatment with an immunosuppressant, patients were followed up monthly. Disease monitoring was undertaken with serial BILAG assessment and serum antinuclear antibody (ANA) status. Treatment of the patients was at the physician's discretion, not dictated by study participation and includes therapy used for induction of remission at enrolment ('induction'). Of a total of 10 patients, 8 were sampled at diagnosis and 2 at disease flare. A minority of patients (3/10) had received prior treatment with oral prednisolone and/or hydroxychloroquine. Samples from patients with Crohn's disease. Patients with active Crohn's disease were recruited from a specialist inflammatory bowel disease (IBD) clinic at Addenbrooke's Hospital, before starting treatment. Of the 23 patients, 22 were recruited at the time of diagnosis. Diagnosis was made using standard endoscopic, histological and radiological criteria 33 . All patients had at least moderately active Crohn's disease at enrolment as evidenced by clinical symptoms in conjunction with some or all of elevated C-reactive protein, elevated faecal calprotectin, radiologically active disease or endoscopically active disease. All patients were treatment naive, with none receiving immunomodulators, corticosteroids or biological therapy. Samples from patients with chronic lymphocytic leukaemia. Patients with chronic lymphocytic leukaemia (CLL) were recruited from the specialist leukaemia and lymphoma unit at Addenbrooke's Hospital between January 2011 and July 2014. CLL patient inclusion required the presence of at least 5 × 10 9 monoclonal B cells per litre of peripheral blood persisting for 3 months and a characteristic phenotype (typically CD5, CD19, CD20 and CD23). Samples from patients with EGPA. Patients with EGPA who attended or were referred to the specialist vasculitis unit at Addenbrooke's Hospital between July 2004 and June 2016 were enrolled. Diagnosis of EGPA was based on the history or presence of both asthma and eosinophilia (>1.0 × 10 9 l −1 and/or >10% of leukocytes) plus at least two additional features of EGPA as per the criteria used in the recent Phase III clinical trial 'Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis' 34 . Of 11 patients in total, 7 were sampled at diagnosis and 4 at disease flare. A minority of patients (4/11) had received prior treatment with oral steroids (methylprednisolone or prednisolone), 2/11 patients had been treated with azathioprine and 1/11 patients treated with cyclophosphamide within 6 months of sampling.
Samples from patients with IgAV and Behçet's disease. Patients with IgAV and
Behçet's disease were recruited from the specialist vasculitis clinic at Addenbrooke's Hospital and enrolled into the present study between 2005 and 2015. The clinical data that were recorded for patients with Behçet's disease were as follows: (i) the basis for diagnosis, that is, orogenital mucosal ulceration, prior ocular inflammation and characteristic skin rash (erythema nodosum or pseudofolliculitis); (ii) major complications such as venous or arterial thrombosis, involvement of the central nervous system or of the pulmonary vascular system; and (iii) disease activity (expert physician global assessment). Of 11 patients, 5 had received prior treatment with oral steroids (prednisolone) and 3 had been treated with azathioprine within 6 months before sampling.
The diagnosis of IgAV was based on the American College of Rheumatology 1990 criteria for the classification of Henoch-Schönlein purpura 35 and the 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides 36 . All patients had to have a biopsy-proven diagnosis of IgAV. Patients were included on the basis of two criteria: i) severe involvement of at least one organ (including biopsy-proven IgAV-related nephritis class 3-4; gastrointestinal involvement with haemorrhage, ischaemia, perforation, and/or abdominal pain unresponsive to common analgesics and lasting for more than 24 h; pulmonary haemorrhage, episcleritis, cardiac and central nervous system involvement); and ii) exclusion of other systemic autoimmune or neoplastic diseases. Of 10 IgAV patients, 8 were sampled at diagnosis and 2 at disease flare; 4/10 patients had received prior treatment with oral prednisolone, 1/10 patients had been treated with azathioprine and 1/10 patients treated with cyclophosphamide within 6 months of sampling. Cell separation, RNA extraction and antibody titres. For PBMCs and CD19 + B cells: PBMCs were isolated from 110 ml of whole blood by centrifugation over Ficoll. CD19 + B cells were isolated by positive selection using magnetic beads as previously described 37 . Total RNA was extracted from each sample using an RNeasy mini kit (Qiagen), quality was assessed using an Agilent BioAnalyser 2100 and RNA quantification was performed using a NanoDrop ND-1000 spectrophotometer.
For flow-sorted B cell samples 38 : flow sorting was performed using CD19-BV785, CD38-BV711, CD3-NC650, CD14-605NC, CD24-PerCP-Cy5.5, IgD-FITC. CD27-PE-Cy7 and Aqua (Invitrogen) (the flow cytometry protocol is outlined in Extended Data Fig. 1 ) into sorting buffer (10 mM Tris pH 8.0 and RiboLock RNase Inhibitor (1 U µl −1 )) and frozen immediately.
Total IgA and IgE levels in patient serum were measured using a ProcartaPlex immunoassay kit (Thermo Fisher Scientific) using 25 µl of serum from each individual and run on a Luminex xMAP analyser. Raw data (MFI) were normalized to a concurrently measured 7-point standard curve according to the manufacturer's instructions to return an absolute quantification (pg ml −1 ). All measured values were encompassed by the standard distribution. Reverse transcription and amplification with barcoded primers. Reverse transcription was performed in a 23-µl reaction: 14 µl of reverse-transcription mix 1 (containing RNA template, 10 µM reverse primer mix, 1 µl dNTP (10 mM) and nuclease-free water) was incubated for 5 min at 70 °C. This mixture was immediately transferred to ice for 1 min, and the reverse-transcription mix 2 (4 µl 5× FS buffer, 1 µl DTT (0.1 M), 1 µl SuperScriptIII (Thermo Fisher Scientific)) was added and incubated at 50 °C for 60 min followed by 15 min inactivation at 70 °C. cDNA was cleaned with Agencourt AMPure XP beads and PCR-amplified with V-gene multiplex primer mix (10 µM each forward primer) and 3′ universal reverse primer (10 µM) using KAPA protocol and the following thermal cycling conditions: 1 cycle (95 °C, 5 min); 5 cycles (98 °C, 5 s; 72 °C, 2 min); 5 cycles (65 °C, 10 s; 72 °C, 2 min); 25 cycles (98 °C, 20 s; 60 °C, 1 min; 72 °C, 2 min); 1 step (72 °C, 10 min). Primers are provided in Supplementary Table 7 . Sequencing and barcode filtering. Sequencing libraries were prepared using Illumina protocols and sequenced using 300-bp paired-end sequencing on a MiSeq (Illumina). Raw reads were filtered for base quality (median Phred score of over 32) using QUASR (http://sourceforge.net/projects/quasr/) 39 . Forward and reverse reads were merged if they contained an identical overlapping region of more than 50 bp, or otherwise discarded. Universal barcoded regions were identified in reads and orientated to read from V-primer to constant-region primer. The barcoded region within each primer was identified and checked for conserved bases. Primers and constant regions were trimmed from each sequence, and sequences were retained only if there was over 80% per base sequence similarity between all sequences obtained with the same barcode; otherwise they were discarded. The constant-region allele with highest sequence similarity was identified by 10-mer matching to the reference constant-region genes from the IMGT database 40 , and sequences were trimmed to give only the region of the sequence that corresponded to the variable (VDJ) regions. Isotype use information for each BCR was retained throughout the analysis hereafter. Sequences without complete reading frames and non-immunoglobulin sequences were removed and only reads with significant similarity to reference IGHV and J genes from the IMGT database using BLAST 41 were retained. Immunoglobulin gene use and sequence annotation were performed in IMGT V-QUEST, and repertoire differences were performed by custom scripts in Python. Accounting for age in the BCR analysis. Age-related differences in the BCR repertoire have been previously described, and this could be important as immunemediated diseases often have different ages of onset. We confirmed this in both healthy controls and disease, and then incorporated age as a covariate in repertoire analyses, as in previous studies [42] [43] [44] .
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As expected, correction for age usually made little difference (Extended Data Fig. 4a ). In cases in which statistical discordance between uncorrected and corrected data did occur, the latter became not significant, indicating that this correction is appropriately conservative (that is, correction does not create spurious statistically significant positive associations). In these and most other cases (predominantly in diseases of later onset (AAV, EGPA)), age correction made P values less significant, which indicates that some observed repertoire differences are driven in part by age, and underlines the importance of correcting for it (Extended Data Fig. 3a-d) . In some cases, results that were already significant became more so after correction; as expected, many of these were in cases of SLE or Crohn's disease, which are diseases with a younger age of onset (Extended Data Fig. 3c ). Isotype frequencies, somatic hypermutation, CDR3 lengths and IGHV gene use. To account for the greater numbers of BCR RNA molecules per plasmablast compared to other B cell subsets, we calculated two measures of isotype use: (i) the percentage of reads per isotype, which does not control for differential RNA per cell and thus reflects the effect that plasmablasts and plasma cells have on the repertoire; and (ii) the normalized isotype use, which is defined as the percentage of unique VDJ sequences per isotype, thus controlling for differential RNA per cell and reducing potential biases from differential RNA per cell. We did not control for ethnicity as the majority of patients (95%) in all disease groups were of northern European ancestry, with the exception of SLE in which four patients were Asian and five were Caucasian. We observed only two IGHV genes that exhibited differential frequencies between ethnicities with an FDR of less than 0.05 ( Supplementary  Table 6 ), and neither of these were differentially expressed between SLE and health.
Similarly, mean somatic hypermutation levels and CDR3 lengths were calculated per unique VDJ region sequence to reduce potential biases from differential RNA per cell. IGHV gene use was determined using IMGT 45 , and proportions were calculated per unique VDJ region sequence. The representation of IGHV genes in the BCR repertoire reflects their presence in the germline, the naive repertoire and their expansion after antigenic exposure. We therefore compared the frequency of IGHV gene use in PBMC-derived BCRs identified by sequence as being enriched for naive B cells (IgM + IgD + SHM − : more than 78% naive B cells by flow cytometry) and antigen-experienced B cells (including both unswitched (IgM + IgD + SHM + ) and class-switched memory (IgA + IgG + IgE + ) subsets). Generation of the BCR repertoire and network analysis. The network generation algorithm and network properties were calculated as described previously 15 : each vertex represents a unique sequence, and the relative vertex size is proportional to the number of identical reads. Edges join vertices that differ by single nucleotide non-indel differences and clusters are collections of related, connected vertices. A clone (cluster) refers to a group of clonally related B cells, each containing BCRs with identical CDR3 regions and IGHV gene use, or differing by single point mutations, such as through SHM. Each cluster is assumed to arise from the same pre-B cell.
Repertoire parameters that were dependent on sequencing depth were generated by subsampling each sequencing sample to a specified depth. First, the clonal expansion index is a measure of the unevenness of the number of RNA molecules per unique VDJ region sequence by vertex Gini Index as defined previously 15 . This is calculated from the distribution of the number of unique RNA molecules per vertex within subsampled BCR repertoires at the specified depth defined below. The mean of 100 repeats of resulting clonal expansion indices was determined. Second, the clonal diversification index is a measure of the unevenness of unique VDJ region sequences per clone by cluster Renyi Index, as defined previously 15 . This is calculated from the distribution of the number of unique VDJ region sequences per clone within subsampled BCR repertoires at the specified depth defined below. The mean of 100 repeats of resulting clonal diversification indices was determined. Clone size distributions were also calculated from the same subsamples and the mean of 100 repeats was determined.
The number of sampled unique RNA molecules (for the clonal expansion index) and clones (for the clonal diversification index) per sample was: all isotypes, 3,500; IgD and IgM mutated, 600; IgD and IgM unmutated, 500; class-switched, 1,000; IgA1/2, 1,000; IgD, 75; IgE, 50; IgG1/2, 500; IgG3, 100; IgM, 750. These thresholds were chosen as a balance between including as many samples as possible per analysis but still remaining representative of the total BCR repertoire in each sample. Sampling of the BCR network to preserve the overall clonal structure of visual representation. We developed network sampling methods to obtain a graphical representation of a network that preserves the overall clonal architecture. The rationale for this development, and for the selection of the clone-sampling method, is discussed in detail in the Supplementary Discussion. In brief, a fixed number of clones were subsampled, and a network was generated from all BCRs from these clones from a given sample. Subsampling was performed 1,000 times, and the sample that contained a maximum clone size closest to the median of all subsamples was chosen to generate a visual representation of the BCR repertoire. Global measure of BCR repertoire. To define a global measure of the clonal normality or otherwise of the BCR repertoire, we combined three main BCR features (isotype frequency, clonal expansion index and clonal diversification index) using a multivariate ANOVA (MANOVA) comparison between disease groups with age as a covariate. Analyses of class-switching events. The relative frequency of class-switching events was the frequency of unique VDJ regions expressed as two isotypes (that is, from more than one B cell, one of which has undergone CSR). This was determined as the proportion of unique BCRs present as both isotypes IgX and IgY within a random subsample of 8,000 BCRs, from which the mean of 1,000 repeats was generated (Extended Data Fig. 7e ). This provides information on the frequency of BCRs observed to be associated with any two isotypes (class-switching events) and accounts for total read depth, but not for differences in the relative frequencies of BCRs per isotype.
The per-isotype normalized class-switch event frequency determines the frequency of unique VDJ regions expressed as two isotypes, normalizing for differences in isotype frequencies. To account for differences in isotype proportions, BCRs from each isotype were randomly subsampled to a fixed depth of 100 BCRs, and the proportion of unique VDJ sequences present between each pair of isotypes was counted (Extended Data Fig. 9a ). The mean of 1,000 repeats was generated. Clonal overlap between time points during therapy. The identification of persistent clones was performed using MRDARCY 46 . Clonal overlap frequencies between samples, including the quantification of persistent clones, were determined through subsampling each repertoire to a fixed depth of 2,000 unique BCRs and determining the proportion of overlapping clones. The mean of 1,000 repeats was generated.
Although quantitative conclusions are difficult as a blood draw samples such a small proportion of peripheral B cells, the clonal overlap estimate between time points is, as expected, significantly lower than that from technical BCR sequencing repeats from the same RNA samples and higher than the overlap between unrelated patient samples (Extended Data Fig. 10d ). Phylogenetic analysis. Phylogenetic trees from patients with AAV and EGPA were derived from all clusters containing at least one BCR sequence across multiple time points using the MRDARCY pipeline 46 . Alignments were performed using MAFFT 47 and maximum parsimony trees fitted using PAUP* 48 . The amino acid similarity tree for IGHV genes was generated using an alignment of reference IGHV genes from IMGT using MAFFT 47 and a maximum parsimony tree was fitted using PAUP* 48 . Statistical methods. Statistical differences between disease groups were performed using ANOVA or MANOVA with patient age as a covariate and correcting for multiple testing by Bonferroni correction. For cases in which patients were age-matched, Wilcoxon tests were performed. Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this paper.
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Methodology

Sample preparation
For PBMCs and CD19+ B cells: PBMCs were isolated from 110 ml of whole blood by centrifugation over Ficoll. CD19+ B cells were isolated by positive selection using magnetic beads as previously described. Total RNA was extracted from each sample using an RNeasy mini kit (Qiagen) with quality assessed using an Agilent BioAnalyser 2100 and RNA quantification performed using a NanoDrop ND-1000 spectrophotometer.
For flow-sorted B cell samples: Flow sorting was performed using CD19-BV785, CD38-BV711, CD3-NC650, CD14-605NC, CD24-PerCP-Cy5.5, IgD-FITC. CD27-PE-Cy7 and Aqua (Invitrogen), where flow protocol is outlined in Figure S1b Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
